<DOC>
	<DOCNO>NCT00113932</DOCNO>
	<brief_summary>The purpose study find treat multiple myeloma ( MM ) patient intense chemotherapy autologous transplant ( high dose density therapy ) early disease course result well treatment outcome compare patient treat past .</brief_summary>
	<brief_title>UARK 2003-41 : A Study High-Dose Density Therapy Patients With Multiple Myeloma</brief_title>
	<detailed_description>This study evaluate whether high-dose density treatment initial seven month , include tandem transplant within six month start therapy , result superior event-free overall survival rate compare historical control .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>Patients symptomatic multiple myeloma , previously treat untreated . Patients previously untreated must eligible UARK 200333 . Karnofsky performance score &gt; 60 % , unless due MM Patients must &lt; 75 year age time registration Patient must prior auto allotransplant Patient must sign IRBapproved informed consent understand investigational nature study . Negative serology HIV . Baseline study within 60 day prior registration ; patient must history chronic obstructive chronic restrictive pulmonary disease . Patients must adequate pulmonary function study &gt; 50 % predict mechanical aspect ( FEV1 , FVC , etc ) diffusion capacity ( DLCO ) &gt; 50 % predict . Patients unable complete pulmonary function test myelomarelated chest pain , must high resolution CT scan chest must also acceptable arterial blood gas define P02 great 70 . Patients recent ( &lt; 6 month ) myocardial infarction , unstable angina , difficult control congestive heart failure , uncontrolled hypertension , difficult control cardiac arrhythmia ineligible . Ejection fraction ECHO must &gt; 40 % must perform within 60 day prior registration , unless patient receive chemotherapy within period time ( dexamethasone thalidomide exclude ) , case LVEF must repeat . Uncontrolled infection define protocol section 5.1.11 Liver function abnormality total bilirubin twice upper limit normal AST ALT three time upper limit normal Severe renal dysfunction , define creatinine &gt; 3mg/dl creatinine clearance &lt; 30ml/min Significant neurotoxicity , define grade &gt; 2 neurotoxicity per NCI Common Toxicity Criteria Platelet count &lt; 100,000/mm3 , ANC &lt; 1,000/μl POEMS Syndrome Clinically significant hepatic dysfunction note direct bilirubin AST &gt; 3 time upper normal limit clinically significant concurrent hepatitis New York Hospital Association ( NYHA ) Class III Class IV heart failure Myocardial infarction within last 6 month Patients history treatment clinically significant ventricular cardiac arrhythmia Poorly control hypertension , diabetes mellitus , serious medical illness psychiatric illness could potentially interfere completion treatment accord protocol Pregnant potential pregnancy . Women childbearing potential pregnancy [ βHCG ] test screening , require use medically approve contraceptive method . Pregnancy test perform prior administration dose study drug Breastfeeding woman may participate Prior adriamycin exposure &gt; 450 mg/m2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Myeloma</keyword>
</DOC>